NHS Cost-Effectiveness Thresholds Boost Drug Ap...

By João L. Carapinha

January 12, 2026

Confirmation of Adjusted Cost-Effectiveness Thresholds for NHS Medicines Evaluations The UK's National Institute for Health and Care Excellence (
Driving Economic Transformation through Brain Health Investment in Africa
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Novartis Drug Pricing Agreement
INFARMED Leadership Appointments: A New Era in Health Regulation and Expertise
Preparing for the EU Health Technology Assessment: Key Insights from the Upco...
Strategic Avalere Health Appointments Enhance Leadership in Navigating US Hea...
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Biomanufacturing Excellence Act: Strengthening U.S. Biopharmaceutical Manufac...
Medicare Drug Price Negotiations: Major Savings for Seniors on Cancer and Chr...
Advancements in Continuous Glucose Monitoring for Type 2 Diabetes Management
NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leuka...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...